SHENZHEN KANGJUZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.;SHENZHEN UNIVERSITY
发明人:
Guangyi Jin,Zhulin Wang
申请号：
US15776784
公开号：
US10711005B2
申请日:
2016.11.08
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Compound I and a compound II as well as preparation methods therefor and use thereof are disclosed. A newly synthesized compound of formula I is capable of stimulating congenital immunity and cellular immunity for tumor resistance while greatly improving the antitumor effect of ethacrynic acid (EA), and thus an integrated synergistic anti-tumor dual-immunity drug design is explored. The immune response mechanism for resisting melanoma of the compound as shown in the formula I is demonstrated. A compound that is as shown in a formula II and is prepared from the compound of formula I and ROR1 by means of covalency markedly slows down the growth of subcutaneously transplanted mammary cancer tumor, such that the immune response mechanism, for treating the mammary cancer, of the compound as shown in the formula II is demonstrated.
